Shares rose after a jump in sales of the blockbuster Dupixent drug and robust pharmaceutical launches delivered higher ...
The drug’s success in a Phase 2 study in alpha-1 antitrypsin deficiency “validates” Sanofi’s 2024 acquisition of Inhibrx, ...
GlobalData on MSN
Dupixent stirs Sanofi’s growth as vaccine sales cool
Dupixent’s Q3 sales increased by 26.2%, breaking through the €4bn ceiling for the first time in a single quarter.
Sanofi gained Rezurock in a $1.9 billion buyout of Kadmon in 2021, less than two months after the FDA approved the treatment ...
The MoU supports Saudi Vision 2030 and the National Transformation Program’s focus on localizing healthcare manufacturing ...
Sanofi’s efdoralprin alfa met all primary and key secondary endpoints in alpha-1 antitrypsin deficiency emphysema phase 2 studyEfdoralprin alfa ...
Q3 2025 Earnings Call October 24, 2025 8:30 AM EDTCompany ParticipantsThomas Larsen - Head of Investor RelationsPaul Hudson - CEO ...
With a new approach to creating thymus-targeted medicines for autoimmune diseases, Zag Bio has emerged from stealth with the ...
Spot shows folks running as a symbol of how the health-challenged can chase their dreams because of Sanofi meds.
An anti-inflammation injectable drug called dupilumab can reduce mucus buildup and improve breathing among asthma patients, a ...
The fireside chats will be webcast live and can be accessed via a link in the Investors section of the Nurix website. The archived webcasts will be available for 30 days after the event. About Nurix ...
Expanded 10-plus-year collaboration will leverage Medidata Experiences, enabling Sanofi to streamline operations, refine data quality, and enhance patient care New York – Oct. 23, 2025 – Medidata, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback